CDKN2A and astrocytoma (excluding glioblastoma): Currently, molecular markers for clinical classification, prognosis, and therapeutic response prediction of astrocytoma include MGMT promoter methylation and homozygous CDKN2A and/or CDKN2B deletions.8, 36, 37